Most Recent Annual Report
2016 Annual Report and Form 10K
FibroGen Inc does not currently have any hardcopy reports available on AnnualReports.com. Click the button below to be notified when hardcopies become available.
FibroGen Inc
FibroGen Inc has reached its limit for report views.
Please check back to see if FibroGen Inc has upgraded their profile page to allow their financial information to be viewed. In the meantime, here are a few annual reports from similar companies.
About FibroGen Inc
201-500 Employees
Based in San Francisco, California
FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing roxadustat, or FG-4592, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; FG-3019, a monoclonal antibody in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage.
- Ticker:
- FGEN
- Exchange:
- NASDAQ (See More NASDAQ Companies)
- Industry:
- Biotechnology (See More Biotechnology Companies)
- Sector:
- Healthcare (See More Healthcare Companies)
